This 2014 preclinical study investigates the combined effects of metformin and tamoxifen on estrogen receptor-positive (ER+) breast cancer cells. The combination therapy significantly inhibited cell proliferation, DNA replication, colony formation, and induced apoptosis more effectively than either agent alone. Mechanistically, the enhanced effects are associated with activation of the AMPK
